NCT06373913View on ClinicalTrials.gov

The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom

RecruitingOBSERVATIONAL

Enrollment

75

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2028

Conditions

HyperlipidemiasNephrotic Syndrome

Trial Locations (1)

6000

RECRUITING

Kolding Sygehus, Lillebælt Hospital, Kolding

All Listed Sponsors

lead

Kolding Sygehus

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Vejle Hospital

OTHER